Altogether, this research verifies the antitumor effects of Aila in NSCLC and further illuminates its mechanism involving DUXAP8 and EGR1. These data all suggest that DUXAP8 has great potential for the diagnosis, treatment, and prognosis of NSCLC, and our results provide a feasible theoretical basis for subsequent studies. This evidence concerns the gene DUXAP8 and non-small cell lung carcinoma.